Using fecal microbiota transplantation to treat constipation in Parkinson's disease
Official title: Evaluation of the Efficacy and Safety of Fecal Microbiota Transplantation for Parkinson's Disease Patients With Constipation
Run by Shanghai Zhongshan Hospital · NCT06388863 · Data updated 2026-11-12
This study is testing whether a treatment using gut bacteria from healthy donors can help people with Parkinson's disease who struggle with constipation.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 40 Years to 75 Years |
| Sex | All |
| Enrollment | 76 (estimated) |
| Sponsor | Shanghai Zhongshan Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | February 21, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2027 |
| Registry record updated | April 4, 2025 |
| Trial ID | NCT06388863 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals aged 40-75 with a diagnosis of Parkinson's disease and specific constipation symptoms.
✕Probably not a fit
Patients with advanced Parkinson's disease or those with other gastrointestinal disorders may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the efficacy and safety of fecal microbiota transplantation (FMT) for treating constipation in patients with Parkinson's disease. Participants are randomly assigned to receive either FMT capsules or placebo capsules for 24 weeks, with assessments conducted to measure improvements in constipation, emotional well-being, and quality of life. Fecal and blood samples will also be collected for further analysis of gut microbiota and levodopa levels. The study aims to provide insights into the potential benefits of FMT in managing gastrointestinal symptoms associated with Parkinson's disease.
Why it matters
Potential benefit: If successful, this treatment could significantly improve constipation and overall quality of life for patients with Parkinson's disease.
How similar studies have gone: While the use of fecal microbiota transplantation is a novel approach in this context, similar studies have shown promising results in other gastrointestinal conditions.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Participants who fulfill Chinese diagnostic criteria for PD (2016 edition), aged 40-75 years; 2. PD Hoehn-Yahr stage 1-3 3. Participants who have at least 2 of the following symptoms in the past 3 months and the symptoms have been present for at least 6 months: ① More than 25% of defecations are laborious; ② More than 25% of defecations consist of hard or lumpy stools; ③ More than 25% of defecations are accompanied by a sensation of incomplete evacuation; ④ More than 25% of defecations are accompanied by a sensation of anorectal obstruction; ⑤ More than 25% of defecations require manual assistance; ⑥ Less than 3 spontaneous bowel movements per week. 4. Have taken a stable dose of anti-Parkinson drugs, antidepressants and antipsychotics for at least 1 month; 5. Absence of red flags such as weight loss, hematochezia and exclusion of other diagnosis; 6. Have signed the informed consent and agree to participate in this study; Exclusion Criteria: 1. Parkinsonism-plus syndrome; 2. Stroke, brain trauma or epilepsy; 3. Have undergone surgery intervention due to PD; 4. Pregnant, planning pregnancy or lactating; 5. Psychiatric disorder or unable to cooperate with treatment and follow-up visit; 6. Immunodeficiency or treatment with immune-modulating medication; 7. Have undergone any abdominal surgery, with the exception of appendectomy, cholecystectomy, caesarean section and hysterectomy; 8. Presence of uncontrolled diabetes, hypertension, thyroid disease or other systemic disease; 9. Use of probiotics or antibiotics within 1 month prior to study entry; 10. Presence of severe diseases related to heart, brain, kidney and lung or concomitant malignancies;
Where it's running
-
180 Fenglin Road
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Principal investigator: Shengdi Wu — Fudan University
- Study coordinator: Shengdi Wu
- Email: wu.shengdi@zs-hospital.sh.cn
- Phone: (86)13817923359
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions
A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.
-
Tributyrin for PSP: a virtual, early-phase study
This study tests whether tributyrin is safe and tolerable in people with Progressive Supranuclear Palsy who are 45 or older, using virtual visits.
-
A look at why Lewy body conditions cause visual hallucinations
This study tests brain‑imaging in people with Lewy body diseases who do or don’t experience visual hallucinations, and in healthy volunteers, to see how brain networks might create these images.
-
How physical activity might help people with Parkinson’s disease who have DBS-STN implants
This study tests whether adding regular physical activity can help people with Parkinson’s who have DBS-STN stimulation by trying a structured physiotherapy approach alongside standard care.
-
Can hippotherapy improve mobility, gait, balance, and quality of life in people with Parkinson's disease?
This pilot trial tests whether adding horse-assisted therapy to standard rehab helps mobility, gait, balance, and perceived health in adults with Parkinson's disease.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.